Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_assertion type Assertion NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_head.
- NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_assertion description "[Although the effect of new drugs such as poly(ADP-ribose) polymerase inhibitors are being investigated in ovarian cancer, there is still a need to develop targeted therapies-especially to tackle mutations in PI3 K pathway, RAS pathway and TP53.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_provenance.
- NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_assertion evidence source_evidence_literature NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_provenance.
- NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_assertion SIO_000772 25473022 NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_provenance.
- NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_assertion wasDerivedFrom befree-2016 NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_provenance.
- NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_assertion wasGeneratedBy ECO_0000203 NP1244677.RARCUxd0bhy9vw_cD10lo_LwJfBiXQYrNm03ryA359pw8130_provenance.